LC-MS/MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-14. Numbers and descriptions here follow the published literature rather than marketing material.
GW501516 acts as a selective agonist at PPARδ, a nuclear receptor that regulates transcription of genes involved in lipid handling and energy metabolism. Activation of PPARδ in preclinical models increases fatty acid oxidation, mitochondrial biogenesis, and exercise endurance in rodents. These effects have made the compound a subject of metabolic research and also a target for sport anti-doping rules. In humans, however, controlled studies are limited, and whether similar endurance or metabolic changes occur at tolerated exposures remains an open question. The receptor’s broad tissue distribution also means downstream effects may vary by organ and condition.
Detection of GW501516 in biological samples generally relies on liquid chromatography coupled with tandem mass spectrometry. Urine is a common matrix in anti-doping analysis, while blood or plasma may be used in research settings. Sample preparation can involve enzymatic hydrolysis, protein precipitation, or solid-phase extraction before instrumental analysis. Because the compound undergoes metabolism, assays may target the parent molecule, one or more metabolites, or both. Detection windows are not fixed; they depend on factors such as dose, route, individual metabolism, and assay sensitivity. Reference standards are required for accurate identification and quantification.
GW501516 acts on PPARδ, a nuclear receptor that helps regulate fatty acid oxidation and energy homeostasis. In animal studies, activation of this receptor was associated with increased endurance and changes in lipid metabolism. Human trials examined effects on blood lipids and other metabolic markers, but the compound did not advance to approval. Rodent studies later reported tumors in multiple tissues at doses used in those experiments. Whether those findings translate to human risk remains uncertain, and the clinical relevance of the animal data is still debated.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual description for typical solid reference material. |
| Solubility | Poorly soluble in water; soluble in DMSO | Solubility depends on solvent, purity, and form. |
| Storage | Cool, dry, protected from light | Long-term storage often uses low temperature and desiccant. |
| Common analytical method | LC-MS/MS | Used for detection and quantification in biological matrices. |
| Common synonyms | GW-501516; GW501516; endurobol | Naming varies among literature, vendors, and databases. |
Anti-doping laboratories identify GW501516 and its metabolites using liquid chromatography-tandem mass spectrometry. Urine is the usual matrix, and detection can occur after the parent compound has cleared from blood. The exact detection window depends on dose, formulation, individual metabolism, and assay sensitivity. Because the compound is prohibited at all times, athletes are subject to testing in and out of competition. Analytical methods continue to improve as new metabolites and designer analogs are characterized.
GW501516 acts as a ligand for PPAR delta, a nuclear receptor that regulates transcription of genes involved in fatty acid oxidation and energy use. Activation of this receptor in skeletal muscle shifts metabolism toward fat burning in animal models. The compound does not burn fat directly; it changes gene expression over hours to days. Researchers study it to understand metabolic flexibility and exercise adaptation. Effects observed in rodents are not automatically expected in humans.
Preclinical research reported that GW501516 increased running endurance in mice and improved lipid profiles in some animal species. Early human trials explored effects on high-density lipoprotein cholesterol, triglycerides, and glucose handling, but the program was discontinued. Published human data are sparse and do not establish efficacy for any condition. Studies also examined PPAR delta in cancer biology, with conflicting findings across models. The relationship between receptor activation, tissue context, and disease risk remains an active area of investigation.
PPARδ is a nuclear receptor that influences transcription of genes involved in fatty acid oxidation, lipid transport, and energy homeostasis. GW501516 binds and activates this receptor with high selectivity relative to PPARα and PPARγ in laboratory assays. Activation alters expression of target genes in skeletal muscle, liver, and adipose tissue in animal models. The exact clinical consequences of these changes in humans remain incompletely characterized, and observed effects in animals do not establish therapeutic benefit or safety.
Published studies have examined GW501516 in animal models of obesity, insulin resistance, and exercise endurance. Early human trials reportedly ended, and development was discontinued after preclinical findings raised concerns about cancer in some rodent studies. Regulatory agencies have not approved cardarine for any medical use. Its availability through non-pharmaceutical channels raises questions about identity, purity, and legal status that are separate from its laboratory pharmacology. Those questions are often addressed through analytical testing rather than assumptions about product labels.
Laboratory handling focuses on identity, purity, and stability. Reference standards are typically stored cold and dry, protected from light, because solutions can degrade over time. Analytical checks may use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Impurities and related substances can be separated chromatographically and compared with a known standard. Because cardarine is not an approved drug, compendial monographs are absent, and laboratories often rely on in-house methods. Reported purity varies among unregulated products and should not be assumed from a label.
GW501516 binds and activates PPARδ, a nuclear receptor that influences transcription of genes involved in fatty acid oxidation and energy use. Activation shifts some metabolic pathways in preclinical models, which is why the compound has been studied for lipid disorders and exercise-related endpoints. The exact downstream effects in humans are incompletely mapped. PPARδ is expressed in many tissues, including skeletal muscle, liver, and adipose tissue, so broad activation may have varied consequences. Researchers continue to examine how selective or partial activation might alter the balance between benefits and risks.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
== Professor of Pathology and Head of Department Chronology == The Professor of Pathology is an established (statutory) chair at the University of Cambridge which was established in 1883. Traditionally, the Professor of Pathology was also the formal Head of department. However, in 2023 Professor Adrian Liston was elected to the Professor of Pathology while Professor Heike Laman was elected 10th Head of department and became the first woman to take on the role since the founding of the department in 1883.
There was a lingering ambiguity in the general notion of "diabetes", especially as it manifests very differently in diabetes mellitus and in diabetes insipidus. In 1843, William Prout aptly summarized the general notion of diabetes of the time as follows:The term diabetes, implying simply an increased flow of urine, is applicable to any disease in which that symptom is present in a remarkable degree. This general use of the term, however, has caused a great deal of confusion; as a variety of diseases differing altogether in their nature, except in the accidental circumstances of being accompanied by diuresis, or a large flow of urine, have in consequence been confounded with one another. To prevent this confusion in future, I would recommend that the term be restricted to those affections in which the urine is saccharine. Hence I define Diabetes to be a disease in which a saccharine state of the urine is the characteristic symptom.
== Characterization == Several qualitative tests are used to detect the presence of reducing sugars. Two of them use solutions of copper(II) ions: Benedict's reagent (Cu2+ in aqueous sodium citrate) and Fehling's solution (Cu2+ in aqueous sodium tartrate). The reducing sugar reduces the copper(II) ions in these test solutions to copper(I), which then forms a brick red copper(I) oxide precipitate. Reducing sugars can also be detected with the addition of Tollens' reagent, which consist of silver ions (Ag+) in aqueous ammonia. When Tollens' reagent is added to an aldehyde, it precipitates silver metal, often forming a silver mirror on clean glassware. 3,5-dinitrosalicylic acid is another test reagent, one that allows quantitative detection. It reacts with a reducing sugar to form 3-amino-5-nitrosalicylic acid, which can be measured by spectrophotometry to determine the amount of reducing sugar that was present. Some sugars, such as sucrose, do not react with any of the reducing-sugar test solutions. However, a non-reducing sugar can be hydrolyzed using dilute hydrochloric acid. After hydrolysis and neutralization of the acid, the product may be a reducing sugar that gives normal reactions with the test solutions. All carbohydrates are converted to aldehydes and respond positively in Molisch's test. But the test has a faster rate when it comes to monosaccharides.
=== Historiography === Historiography of communist states is polarised. According to John Earl Haynes and Harvey Klehr, historiography is characterised by a split between traditionalists and revisionists. "Traditionalists", who characterise themselves as objective reporters of an alleged totalitarian nature of communism and communist states, are criticised by their opponents as being anti-communist, even fascist, in their eagerness on continuing to focus on the issues of the Cold War. Alternative characterisations for traditionalists include "anti-communist", "conservative", "Draperite" (after Theodore Draper), "orthodox", and "right-wing"; Norman Markowitz, a prominent "revisionist", referred to them as "reactionaries", "right-wing romantics", "romantics", and "triumphalist" who belong to the "HUAC school of CPUSA scholarship". According to Haynes and Klehr, "revisionists" are more numerous and dominate academic institutions and learned journals. A suggested alternative formulation is "new historians of American communism", but that has not caught on because these historians describe themselves as unbiased and scholarly and contrast their work to the work of anti-communist traditionalists whom they would term biased and unscholarly. Academic Sovietology after World War II and during the Cold War was dominated by the "totalitarian model" of the Soviet Union, stressing the absolute nature of Stalin's power. The "revisionist school" beginning in the 1960s focused on relatively autonomous institutions which might influence policy at the higher level.
Sources: en.wikipedia.org
Tiredness (fatigue) Dizziness Headaches Cold hands and feet Pale skin Dark urine Jaundice Chest pain Pain in the back or legs Vomiting or diarrhea Heart problems such as an irregular heartbeat (arrhythmia), a heart murmur, an enlarged heart, or heart failure. These may occur because the heart has to work harder to make sure the body gets enough healthy red blood cells. Many people with CAD also experience pain and bluish coloring of the hands and feet (acrocyanosis) or Raynaud's disease. These symptoms result from slow or poor circulation and can range from mild to disabling. Other signs and symptoms of CAD may include enlargement of the spleen (splenomegaly) and mottled discoloration of the skin (livedo reticularis). In people with secondary CAD (associated with another underlying condition), there may be additional signs and symptoms depending on the condition present. For example: Mycoplasma pneumoniae infection (the most common cause of secondary CAD) may cause respiratory symptoms. Various infections or cancers may cause enlarged or swollen lymph nodes.
In biology, homeostasis (in British English also homoeostasis) is the process by which living organisms maintain relatively stable internal physical and chemical conditions despite changes in their internal or external environment. Body temperature, blood glucose, blood pressure, fluid balance, levels of oxygen and carbon dioxide in the blood, pH, and the concentrations of ions such as sodium, potassium, and calcium are all homeostatically regulated variables. These variables are generally maintained within physiological ranges rather than at absolutely constant values; set points for some regulated variables may also change, as occurs with circadian variation in body temperature or during fever. Homeostatic regulation commonly operates through negative feedback. Sensors detect changes in a regulated variable, control mechanisms coordinate an appropriate response, and effectors act to counter the deviation. Regulation can involve the nervous system, endocrine system, and organs: the kidneys, lungs, liver, and pancreas, as well as cellular mechanisms such as the regulation of gene expression. Predictive homeostasis consists of anticipatory responses to expected changes, but these require feedback mechanisms to correct deviations. Together, homeostatic processes maintain conditions in which metabolism and other physiological functions can occur. The concept of regulation of the internal environment was developed in the 19th century by the French physiologist Claude Bernard, and the term homeostasis was coined by the American physiologist Walter Bradford Cannon in 1926.
Nanohedron.com images of nanoparticles Lectures on All Phases of Nanoparticle Science and Technology Archived 29 August 2010 at the Wayback Machine ENPRA – Risk Assessment of Engineered NanoParticles EC FP7 Project led by the Institute of Occupational Medicine
Oplophorus-luciferin 2-monooxygenase (EC 1.13.12.13), also known as Oplophorus luciferase (referred in this article as OpLuc) is a luciferase, an enzyme, from the deep-sea shrimp Oplophorus gracilirostris, belonging to a group of coelenterazine luciferases. Unlike other luciferases, it has a broader substrate specificity and can also bind to bisdeoxycoelenterazine efficiently. It was the third example of a luciferase (Other than Aequorea and Renilla) to be purified in lab. The systematic name of this enzyme class is Oplophorus-luciferin:oxygen 2-oxidoreductase (decarboxylating). This enzyme is also called Oplophorus luciferase.
are the concentrations of the solute's ionic constituents in a saturated solution. The solubility product is derived from and functions like the equilibrium constant of dissociation, though unlike an equilibrium constant it is not dimensionless. If the product of ionic concentrations in a solution exceeds the solubility product, then precipitation occurs.
Sources: en.wikipedia.org
Cardarine targets PPARδ, a nuclear receptor involved in lipid and energy metabolism. It does not bind the androgen receptor in the way SARMs do.
Most methods use liquid chromatography with tandem mass spectrometry. Urine is common in anti-doping testing, and blood or plasma may be used in research.
Typical guidance is cool, dry, dark storage, often at low temperature and with desiccant. Stability data are limited, so storage conditions should be verified for each batch or supplier.
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.